ADMA Biologics posts 3Q 2026 revenue growth of 5% and 31% rise in ASCENIV sales, boosting net income and earnings per share.

ADMA Biologics reported a 5% increase in total revenue to $141.1 million for Q3 2026, driven by a 31% surge in ASCENIV sales to $124.7 million. The company saw a 37% rise in GAAP net income to $49.9 million and a 47% increase in GAAP basic EPS to $0.22, reflecting strong demand and expanding margins. ADMA reaffirmed its 2026 revenue guidance of at least $530 million and raised its adjusted net income and EBITDA outlook, while advancing development of its SG-001 product with positive FDA feedback. These results highlight ADMA's growing market presence and potential for sustained profitability.

Following ADMA Biologics' strong Q3 financial results and optimistic business update, the company's stock price on Pluang has risen notably. As of Nov 05, 2026 04:11 WIB, ADMA trades at USD 12.49, up 12.42% for the day, with a market capitalization of $2.49 billion. Despite this price increase, all recent Pluang order activity shows selling interest, indicating mixed investor sentiment.